Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
Clinical trial NCT01813253 · TERMINATED
Trial details
- NCT number
- NCT01813253
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-05-13
- Primary completion
- 2018-02-19
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.